Latest / Stock Movers / BP Spin Off, Abivax's 1600% Gains, B&M's Woes
Transcript
- 0:00Speaker 1: Bloomberg Audio Studios, podcasts, radio news, The Stock Movers Report,
- 0:10Speaker 1: your roundup of companies making moves in the stock market,
- 0:13Speaker 1: harnessing the power of Bloomberg Data.
- 0:16Speaker 2: Let's take a look at some of the individual stocks
- 0:19Speaker 2: on the move today here in Europe. I'm Caroline Hebkear
- 0:22Speaker 2: and I'm joined by Kit Rees. So Kit thanks for
- 0:27Speaker 2: being with me. BP ouseing their CEO last week. Now
- 0:31Speaker 2: they're getting rid of a whole division. What's the news.
- 0:35Speaker 3: Yes, So it's been a busy few weeks of newsflow
- 0:37Speaker 3: for BP, the oil major. So it's agreed to sell
- 0:41Speaker 3: a majority steak in its castrol business to Stone Peak Partners.
- 0:45Speaker 3: So this is part of its plans to divest some
- 0:48Speaker 3: of the assets from its portfolio. So we'll raise about
- 0:50Speaker 3: six billion dollars for sixty five percent stake in the group.
- 0:54Speaker 3: And it looks like the deal is set to complete
- 0:56Speaker 3: to the end of next year. So BP's been grappling
- 0:58Speaker 3: with quite a few issues. It made a sort of
- 1:01Speaker 3: unsuccessful foray into the renewables world, so now it's pivoting
- 1:04Speaker 3: back to focus on fossil fuels, and it's had pressure
- 1:07Speaker 3: from activist investor Elliott in order to kind of accelerate
- 1:11Speaker 3: this revap. So this is part of the move to
- 1:14Speaker 3: kind of go towards oil and gas and away from
- 1:16Speaker 3: other parts of the business. So the shares this morning
- 1:20Speaker 3: that I've just zero point one percent, which is quite
- 1:22Speaker 3: a small move, but it looks like a good move
- 1:25Speaker 3: in the right direction. Investors will probably be quite pleased
- 1:29Speaker 3: about us. But you know, the outlook for next year,
- 1:31Speaker 3: we'll have to see how much more VP does, what
- 1:33Speaker 3: its new CEO is going to be doing in terms
- 1:35Speaker 3: of strategy, and to see if the shares can can
- 1:39Speaker 3: continue to recover.
- 1:41Speaker 2: Yeah, absolutely, that is the one for us to think about.
- 1:44Speaker 2: Then in the new year, as a VP does seem
- 1:48Speaker 2: to be seeing its share price increase. In terms of
- 1:52Speaker 2: other things that we're thinking about. Is that time of
- 1:54Speaker 2: year where we hand out some informal awards. You're giving
- 2:00Speaker 2: a gong to Abivas.
- 2:02Speaker 3: Why yes. So this is a French biotechnology company, and
- 2:07Speaker 3: biotech tends to be quite a binary Beth investors. So
- 2:11Speaker 3: these companies have drugs in development and either the trial
- 2:16Speaker 3: results are positive and we see huge kind of rallies
- 2:19Speaker 3: in the shares, or the negative and you can see
- 2:21Speaker 3: very big falls. So Abuvax's shares are up more than
- 2:24Speaker 3: one six hundred percent this year, making it easily the
- 2:28Speaker 3: top perform in the stock six hundred index, basically because
- 2:31Speaker 3: it got positive trial results for its bow disease drug.
- 2:35Speaker 3: So this is a positive development for the company. Biotechs
- 2:39Speaker 3: which have successful trial results can attract M and A interest,
- 2:43Speaker 3: especially from US companies. But they're going to be a
- 2:46Speaker 3: few key catalysts we'll be watching out for next year.
- 2:49Speaker 3: So it's going to get its Phase three maintenance results
- 2:52Speaker 3: for its ulcerative colitis treatment in the second quarter, and
- 2:55Speaker 3: there's also going to be some trial results for its
- 2:57Speaker 3: crone disease treatment in the second half. So we'll have
- 3:01Speaker 3: to see if it can sustain these absolutely enormous gains
- 3:04Speaker 3: which are putting it on track forwards best year on record.
- 3:07Speaker 2: Okay, I like to think about that stock then an
- 3:11Speaker 2: interesting one. Not everyone though, get us to be the best,
- 3:15Speaker 2: So tell us about B and M kit.
- 3:18Speaker 3: Yeah, so this is sadly the second worst performer in
- 3:21Speaker 3: the stock six hundred index the shares, but the B
- 3:23Speaker 3: and M shares have more than half this year, and
- 3:27Speaker 3: it's on track Ford's worst year on record, following also
- 3:30Speaker 3: what was a pretty underwhelming twenty twenty four, so it's
- 3:33Speaker 3: been a sort of a series of unfortunate events. The
- 3:36Speaker 3: company is grappling with the higher cost of hiring and
- 3:39Speaker 3: also rising competition from lower cost rivals. It operates in
- 3:43Speaker 3: the discount retailer segment of the market, and low income households,
- 3:48Speaker 3: who are kind of its main customers, have also been
- 3:51Speaker 3: grappling with the cost of living crisis, so the company's
- 3:55Speaker 3: cut guidance several times this year. It's CUFO has exited
- 3:58Speaker 3: following an accounting error, and it's also got a relatively
- 4:01Speaker 3: new CEO, and he said that the turnaround could take
- 4:04Speaker 3: up to eighteen months, so we'll have to see how
- 4:07Speaker 3: this pans out for BNM next year to see if
- 4:09Speaker 3: it can deliver on its revamp. It said that it's
- 4:12Speaker 3: looking to do things such as cutting key food prices
- 4:16Speaker 3: and reducing the number of products, but it could be
- 4:18Speaker 3: a long way for the chefs to recover next year.
- 4:23Speaker 1: This Stock Movers report from Bloomberg Radio. Check back with
- 4:27Speaker 1: us throughout the day for the latest roundup of companies
- 4:30Speaker 1: making news on Wall Street and for the latest market
- 4:33Speaker 1: moving headlines. Listen to Bloomberg Radio Live catch US on YouTube,
- 4:37Speaker 1: Bloomberg dot com, and on Applecarplay and Android Auto with
- 4:41Speaker 1: the Bloomberg Business app.